Details

Autor(en) / Beteiligte

• Joura, Elmar A
• Ault, Kevin A
• Bosch, F Xavier
• Brown, Darron
• Cuzick, Jack
• Ferris, Daron
• Garland, Suzanne M
• Giuliano, Anna R
• Hernandez-Avila, Mauricio
• Huh, Warner
• Iversen, Ole-Erik
• Kjaer, Susanne K
• Luna, Joaquin
• Miller, Dianne
• Monsonego, Joseph
• Munoz, Nubia
• Myers, Evan
• Paavonen, Jorma
• Pitisuttithum, Punnee
• Steben, Marc
• Wheeler, Cosette M
• Perez, Gonzalo
• Saah, Alfred
• Luxembourg, Alain
• Sings, Heather L
• Velicer, Christine

Titel

Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease

Ist Teil von

• Cancer epidemiology, biomarkers & prevention, 2014-10, Vol.23 (10), p.1997-2008

Ort / Verlag

United States

Erscheinungsjahr

2014

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• We estimated the prevalence and incidence of 14 human papillomavirus (HPV) types (6/11/16/18/31/33/35/39/45/51/52/56/58/59) in cervicovaginal swabs, and the attribution of these HPV types in cervical intraepithelial neoplasia (CIN), and adenocarcinoma in situ (AIS), using predefined algorithms that adjusted for multiple-type infected lesions. A total of 10,656 women ages 15 to 26 years and 1,858 women ages 24 to 45 years were enrolled in the placebo arms of one of three clinical trials of a quadrivalent HPV vaccine. We estimated the cumulative incidence of persistent infection and the proportion of CIN/AIS attributable to individual carcinogenic HPV genotypes, as well as the proportion of CIN/AIS lesions potentially preventable by a prophylactic 9-valent HPV6/11/16/18/31/33/45/52/58 vaccine. The cumulative incidence of persistent infection with ≥1 of the seven high-risk types included in the 9-valent vaccine was 29%, 12%, and 6% for women ages 15 to 26, 24 to 34, and 35 to 45 years, respectively. A total of 2,507 lesions were diagnosed as CIN or AIS by an expert pathology panel. After adjusting for multiple-type infected lesions, among women ages 15 to 45 years, these seven high-risk types were attributed to 43% to 55% of CIN1, 70% to 78% of CIN2, 85% to 91% of CIN3, and 95% to 100% of AIS lesions, respectively. The other tested types (HPV35/39/51/56/59) were attributed to 23% to 30% of CIN1, 7% to 14% of CIN2, 3% to 4% of CIN3, and 0% of AIS lesions, respectively. Approximately 85% or more of CIN3/AIS, >70% CIN2, and approximately 50% of CIN1 lesions worldwide are attributed to HPV6/11/16/18/31/33/45/52/58. If 9-valent HPV vaccination programs are effectively implemented, the majority of CIN2 and CIN3 lesions worldwide could be prevented, in addition to approximately one-half of CIN1.